Cargando…

Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer

Detalles Bibliográficos
Autores principales:	De Giglio, Andrea, Di Federico, Alessandro, Metro, Giulio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554691/ https://www.ncbi.nlm.nih.gov/pubmed/36248330 http://dx.doi.org/10.21037/tlcr-22-492

Ejemplares similares

Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents
por: Wrona, Anna, et al.
Publicado: (2021)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
por: Addeo, Alfredo, et al.
Publicado: (2018)

Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
por: Metro, Giulio, et al.
Publicado: (2022)

Advanced non-small-cell lung cancer: how to manage non-oncogene disease
por: De Giglio, Andrea, et al.
Publicado: (2022)

The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks
por: De Giglio, Andrea, et al.
Publicado: (2023)

Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
por: Ciciola, Paola, et al.
Publicado: (2020)

Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
por: Tan, Aaron C., et al.
Publicado: (2022)

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
por: Lou, Na-Na, et al.
Publicado: (2016)

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
por: Addeo, Alfredo, et al.
Publicado: (2019)

Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?
por: Metro, Giulio, et al.
Publicado: (2020)

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
por: Marinelli, Daniele, et al.
Publicado: (2022)

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors is the treatment option of previously treated advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration
por: Yang, Xiaobo, et al.
Publicado: (2022)

Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer in China: a multicenter, single-arm trial
por: He, Zhen, et al.
Publicado: (2022)

Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non–Small Cell Lung Cancer
por: Liao, Dehua, et al.
Publicado: (2022)

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
por: Ricciuti, Biagio, et al.
Publicado: (2017)

Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
por: Metro, Giulio, et al.
Publicado: (2021)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer
por: Fang, Likui, et al.
Publicado: (2021)

Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients
por: Xie, Xiaohong, et al.
Publicado: (2023)

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement
por: Oya, Yuko, et al.
Publicado: (2020)

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
por: Song, Yuxiao, et al.
Publicado: (2020)

Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?
por: Granet-Vaissiere, Estelle, et al.
Publicado: (2023)

Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma
por: Li, Xiaomi, et al.
Publicado: (2022)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis
por: Lee, Tai-Huang, et al.
Publicado: (2022)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Non-small-cell lung cancer: how to manage EGFR-mutated disease
por: Pecci, Federica, et al.
Publicado: (2022)

Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer
por: Liang, Hongge, et al.
Publicado: (2019)

Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
por: Britschgi, Christian, et al.
Publicado: (2020)

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells
por: Tanizaki, J, et al.
Publicado: (2012)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
por: Huang, Ming-Hung, et al.
Publicado: (2022)

Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
por: Koulouris, Andreas, et al.
Publicado: (2022)

Clinical and computed tomography characteristics of non‐small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR‐negative lung cancer
por: Mori, Mio, et al.
Publicado: (2019)

Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer
por: Giunta, Emilio Francesco, et al.
Publicado: (2022)

Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
por: Comunanza, Valentina, et al.
Publicado: (2017)

Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
por: Rothschild, Sacha I.
Publicado: (2015)

Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer
por: Sweis, Randy F, et al.
Publicado: (2016)

The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review
por: Nardone, Valerio, et al.
Publicado: (2023)

Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets
por: Dalurzo, Mercedes L, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kk7l11qn06jqabkcmvgbkr3din